A Phase 1 interventional study of SAD: subcutaneous injection in the abdomen and MAD: subcutaneous injection in the abdomen in Healthy Participants and Overweight or Obese Participants, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Overweight by Innovent Biologics, Inc. — 5 open to participants now, 7 under way, 3 of them phase 3. Overweight · Innovent Biologics, Inc..
Among the 12 studies in Overweight by Innovent Biologics, Inc., this one is the 8th largest by planned enrollment, is one of 4 that started in 2026, is one of 6 in phase 1, and was the 10th registered.
3,620 studies on the registry are indexed under Overweight; 862 are open to participants now.
Browse Overweight studies →5 of the 12 studies in Overweight by Innovent Biologics, Inc. are open now, in 1 country. Recruiting first, the newest first:
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–65
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18+
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 12–18
By country, each count listing its studies:
Of the 535 Overweight studies recruiting now, 160 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 2 · Phase 3 4
First in 2020; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is above the median of 78 across 3,139 interventional studies indexed under Overweight.
Median enrollment 116 across the 12 interventional studies. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Innovent Biologics (Suzhou) Co. Ltd., one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
4 of the studies in Overweight by Innovent Biologics, Inc. that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06884293Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | 2026-12-31 |
| NCT07255209Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study of IBI362 in Chinese Adolescents With Obesity or Overweight | 2027-10-31 |
| NCT07793019Innovent Biologics (Suzhou) Co. Ltd.IBI3042 Study in Healthy Participants and Overweight or Obese Participants | 2027-09-06 |
| NCT07765160Innovent Biologics (Suzhou) Co. Ltd.Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants | 2027-11-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 12 studies in Overweight by Innovent Biologics, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical trials of IBI3040 with single-dose administration in healthy participants and multiple-dose administration in overweight or obese participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants in Part A (SAD) and Part B (MAD) must meet inclusion criteria 1-3:
Participants of Part A (SAD) also need to meet inclusion criteria 4-6:
Participants of Part B (MAD) also need to meet inclusion criteria 7-8:
Exclusion Criteria:
All participants in Part A (SAD) and Part B (MAD) who meet any one of the exclusion criteria 1-17 cannot be included in the corresponding stage of the study:
Participants in Part A (SAD) cannot be included in the study if they meet the following exclusion criteria:
- 18. During the screening period, the systolic blood pressure is less than 90mmHg or ≥140mmHg, or the diastolic blood pressure is less than 50 mmHg or ≥90mmHg, or the pulse rate is less than 60 beats per minute or >100 beats per minute.
Participants in Part B (MAD) who meet any one of the exclusion criteria 19-25 cannot be included in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IBI3040, specification 0.6 ml:2.4 mg, injection, subcutaneous injection in the abdomen
Drug: SAD: subcutaneous injection in the abdomen · Drug: MAD: subcutaneous injection in the abdomen
IBI362, specifications: 0.5 ml:2 mg, 0.5 ml:4 mg and 0.5 ml:6 mg, injection, subcutaneous injection in the abdomen
Drug: MAD: subcutaneous injection in the abdomen
IBI3040 Placebo (without active ingredients), specification 0.6ml, injection, subcutaneous injection in the abdomen
Drug: SAD: subcutaneous injection in the abdomen · Drug: MAD: subcutaneous injection in the abdomen
SAD: Single subcutaneous administration, with a safe follow-up period of 60 days
MAD: Multiple administration, subcutaneous injection
SAD: The incidence rate of adverse events (AE)
Time frame: through study completion, an average of 60 days
SAD: The incidence rate of serious adverse events (SAE)
Time frame: through study completion, an average of 60 days
SAD: Number of subjects with clinically significant changes in physical examination results
Time frame: through study completion, an average of 60 days
SAD: Number of subjects with clinically significant changes in vital signs
Vital signs including body temperature, pulse, respiratory rate and blood pressure
Time frame: through study completion, an average of 60 days
SAD: Number of participants with abnormal laboratory tests results
laboratory tests including Blood routine、Blood Biochemistry (including blood lipids)、Coagulation routine、Urine routine、blood amylase、blood lipase、Pregnancy test、Calcitonin and Glycated hemoglobin (HbA1c)
Time frame: through study completion, an average of 60 days
SAD: Number of subjects with clinically significant changes in twelve-lead electrocardiogram
Time frame: through study completion, an average of 60 days
MAD: The incidence rate of adverse events (AE)
Time frame: through study completion, an average of 20 weeks
MAD: The incidence rate of serious adverse events (SAE)
Time frame: through study completion, an average of 20 weeks
MAD: Number of subjects with clinically significant changes in physical examination results
Time frame: through study completion, an average of 20 weeks
MAD: Number of subjects with clinically significant changes in vital signs
Vital signs including body temperature, pulse, respiratory rate and blood pressure
Time frame: through study completion, an average of 20 weeks
MAD: Number of participants with abnormal laboratory tests results
laboratory tests including Blood routine、Blood Biochemistry (including blood lipids)、Coagulation routine、Urine routine、blood amylase、blood lipase、Pregnancy test、Calcitonin and Glycated hemoglobin (HbA1c)
Time frame: through study completion, an average of 20 weeks
MAD: Number of subjects with clinically significant changes in twelve-lead electrocardiogram
Time frame: through study completion, an average of 20 weeks
SAD: area under the curve (AUC)
Time frame: through study completion, an average of 60 days
SAD: maximum concentration (Cmax)
Time frame: through study completion, an average of 60 days
SAD: time to maximum concentration (Tmax)
Time frame: through study completion, an average of 60 days
SAD: clearance (CL/F)
Time frame: through study completion, an average of 60 days
SAD: apparent volume of distribution (V/F)
Time frame: through study completion, an average of 60 days
SAD: half-life (T1/2)
Time frame: through study completion, an average of 60 days
SAD: Anti-drug antibodies (ADA)
Time frame: through study completion, an average of 60 days
SAD: neutralizing antibodies (NAb)
Time frame: through study completion, an average of 60 days
MAD: area under the curve (AUC)
Time frame: through study completion, an average of 20 weeks
MAD: maximum concentration (Cmax)
Time frame: through study completion, an average of 20 weeks
MAD: time to maximum concentration (Tmax)
Time frame: through study completion, an average of 20 weeks
MAD: clearance (CL/F)
Time frame: through study completion, an average of 20 weeks
MAD: apparent volume of distribution (V/F)
Time frame: through study completion, an average of 20 weeks
MAD: half-life (T1/2)
Time frame: through study completion, an average of 20 weeks
MAD: Anti-drug antibodies (ADA)
Time frame: through study completion, an average of 20 weeks
MAD: neutralizing antibodies (NAb)
Time frame: through study completion, an average of 20 weeks
MAD: The change in body weight from baseline and the rate of change
Time frame: through study completion, an average of 20 weeks
Start is estimated for Aug 2026; primary completion for Nov 2027, 14 months later.
Of 215 industry-sponsored phase 1 interventional studies under Overweight, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 14 months is above that.
Counting every sponsor, half of 234 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innovent Biologics (Suzhou) Co. Ltd. →